Papillary Renal Cell Carcinoma Type 2: Clinical Trials

3 trials for Papillary Renal Cell Carcinoma Type 2, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 unknown, 1 completed. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Unknown 2, Completed 1

Follow Papillary Renal Cell Carcinoma Type 2: new trials by email Literature Review of Papillary Renal Cell Carcinoma Type 2 trials Research Report on Papillary Renal Cell Carcinoma Type 2

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC
Axitinib Oral Tablet [Inlyta], Pembrolizumab Injection [Keytruda] - Papillary Renal Cell Carcinoma Type 2
Phase 2UnknownCentre Leon Berard722022-06-012024-01-25
ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)
Cabozantinib - Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1
Phase 2CompletedAustralian and New Zealand Urogenital and Prostate Cancer Trials Group352019-04-112025-08-08
Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)
Nivolumab, Ipilimumab - Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1
Phase 2UnknownAustralian and New Zealand Urogenital and Prostate Cancer Trials Group852017-10-192022-02-16

Narrower conditions

Carcinoma, Renal Cell (2)

Broader conditions

Adenocarcinoma (2)  ·  Carcinoma (2)  ·  Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)  ·  Kidney Diseases (2)  ·  Kidney Neoplasms (2)  ·  Male Urogenital Diseases (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms by Site (2)  ·  Neoplasms, Glandular and Epithelial (2)  ·  Urogenital Diseases (2)  ·  Urogenital Neoplasms (2)  ·  Urologic Diseases (2)  ·  Urologic Neoplasms (2)

Interventions

Axitinib (1)  ·  Ipilimumab (1)  ·  Nivolumab (1)  ·  cabozantinib (1)  ·  pembrolizumab (1)

Sponsors

Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2)  ·  Centre Leon Berard (1)

Countries

Australia (2)  ·  France (1)

Top investigators

David Pook, MBBS FRACPMD (1)